Imugene (IMU) Short Interest
Imugene (ASX:IMU) had 0.39% of shares reported as short positions as of 24 Aug 2026, representing 1,914,882 shares. Imugene operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Imugene
Imugene is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer treatment. Their pipeline includes B-cell immunotherapies and oncolytic virotherapy technologies designed to activate the immune system against cancer cells. Imugene aims to improve the lives of cancer patients by creating more effective and tolerable treatments.
Short position
Imugene (ASX:IMU) has 0.39% of its shares on issue reported as short positions as of 24 Aug 2026, or about 1,914,882 shares. Over the past 30 days that figure has fallen 0.75 percentage points, and over 90 days it has fallen 1.15 percentage points. Its highest recorded short interest was 7.25% in November 2023. IMU is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 35, 2026.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4IMU intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Imugene
About
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss IMU
Start a research thread or post the first pulse update